Clinical Trials Logo

Clinical Trial Summary

Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. These immunosuppressive mechanisms will be better characterized and their involvement in therapeutic responses in non-small cell lung cancers (NSCLC). Indeed, large transcriptomic analysis of different subsets of immunosuppressive cells will performed, correlating them to clinical outcome in a cohort of stage III disease, treated by radiochemotherapy and immunotherapy as maintenance, and stage IV treated by immunotherapy as first-line treatment. Furthermore, we will analyse cellular mechanisms by in vitro studies, assessing the effect of immunosuppressive cells, provided by fresh tumor samples, on phenotype and functions of lung cancer cell lines. The aim of this study is to better characterize immunosuppressive landscape of NSCLC and mechanisms involved in their protumor functions.


Clinical Trial Description

In recent years, immune-based therapies have revolutionized the field of oncology by significantly improving survival of cancer patients. Despite sustained responses, only 20% to 40% of cancer patients respond. It has become clear that the immunosuppressive environment induced by tumor through cellular and/or soluble pathways critically contribute to hinder efficient antitumor immunity. The inhibition of these immunosuppressive networks thus represents an essential prerequisite for the improvement of responses to anticancer immunotherapies. Several immune and non -immune cell populations have been identified as key actors of tumor-induced immunosuppression, among which are myeloid-derived suppressor cells (MDSC), and cancer associated fibroblasts (CAF). However, in non-small cell lung cancers (NSCLC), the phenotypic characteristics and the prognostic role of these cells, the mechanisms underlying their immunosuppressive functions, and their role in dampening the efficacy of immunotherapies in clinical practice are less characterized. The aim of this project is to better characterize these different immunosuppressive subpopulations, and to study their role promoting NSCLC development and resistance to immunotherapies. First the tumor CAF and immunosuppressive microenvironment using single cell RNA sequencing will be characterized (objective 1a). After identification of phenotypic markers, the immunosuppressive landscape of stage III NSCLC on a lung cancer cohort treated at Bordeaux University Hospital will be analysed, and data on CAF, MDSC and immune infiltration will be correlated with tumor characteristics and cancer outcome (objective 1b). Finally, the pro-tumor functions of CAF isolated from lung cancer patients will be assessed in vitro (objective 2). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06024538
Study type Observational
Source University Hospital, Bordeaux
Contact Charlotte DOMBLIDES
Email charlotte.domblides@chu-bordeaux.fr
Status Not yet recruiting
Phase
Start date October 2023
Completion date October 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Completed NCT04508270 - Significance of Early Mobilization After VATS-L
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT05469425 - Home-based Preoperative Exercise Training for Lung Cancer Patients Undergoing Surgery N/A
Recruiting NCT05046067 - Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery N/A
Terminated NCT03090880 - Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) Phase 3
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Completed NCT02498860 - Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung Phase 2
Completed NCT02952261 - Application of 3D Printing Technique in Small Pulmonary Nodule Localization N/A
Recruiting NCT02965300 - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis N/A
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Recruiting NCT00765986 - Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy N/A
Completed NCT03320044 - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting NCT03655015 - Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Completed NCT03741868 - Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
Not yet recruiting NCT05179408 - Telerehabilitation Following Lung Cancer N/A
Completed NCT03749512 - NLCR in Prediction of the Grade of Lung Tumor.
Recruiting NCT03664843 - Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Completed NCT01261507 - Reader Study of DeltaView™ Chest Radiograph Software N/A
Terminated NCT01064050 - Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers Phase 4